SCHEMBL26099566

SCHEMBL26099566

O=C(Nc1cccc(Cl)c1)c1c2c(nc3cc(Cl)ccc13)CCN(CCc1ccccc1)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.56
▸ GAA P10253 1/20 0.56
▸ MAPT P10636 7/20 0.51
▸ ALDH1A1 P00352 8/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ TP53 P04637 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MAPK1 P28482 2/20 0.48
▸ PRMT5 O14744 1/20 0.46
▸ WDR77 Q9BQA1 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ USP7 Q93009 1/20 0.44
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26100377 0.94 LMNA (0.55) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26097193 0.93 MAPT (0.57) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26098861 0.91 MAPT (0.51) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26097738 0.90 MAPT (0.54) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26098494 0.88 MAPT (0.56) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26099407 0.88 MAPT (0.50) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26099622 0.87 MAPT (0.56) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL31666079 0.86 ALDH1A1 (0.48) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26098464 0.86 ALDH1A1 (0.48) LMNAGAAMAPTALDH1A1SMN1; SMN2
SCHEMBL26454732 0.86 MAPT (0.68) LMNAGAAMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370183-B2 Compositions and methods for treating malaria G6PD, QDPR, FASN LMNA 969/4885GAA 269/4885MAPT 1034/4885
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA G6PD, QDPR, FASN LMNA 969/4885GAA 269/4885MAPT 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback